Acción STAB STATERA BIOPHARMA, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Statera Biopharma, Inc. Nasdaq

Acciones

STAB

US8575611046

Mercado cerrado - Nasdaq
Otros sitios de cotización
 15:30:01 20/05/2024 		Varia. Cinco días. Varia. 1 de enero.
0,0007 USD 0,00 % Gráfico intradía de Statera Biopharma, Inc. 0,00 % -99,98 %
2022 Statera Biopharma, Inc. informa de los resultados del tercer trimestre y de los nueve meses finalizados el 30 de septiembre de 2022 CI
2022 Statera Biopharma, Inc. informa de los resultados del segundo trimestre y de los seis meses finalizados el 30 de junio de 2022 CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Statera Biopharma, Inc. entered into a letter of intent to acquire Worksite Labs.
STATERA BIOPHARMA, INC. : Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
STATERA BIOPHARMA, INC. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits (form 8-K)
Statera Biopharma, Inc.(OTCPK:STAB) dropped from S&P TMI Index
Statera Biopharma, Inc.(OTCPK:STAB) dropped from NASDAQ Composite Index
STATERA BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
STATERA BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Statera Biopharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Statera Biopharma : Material Agreement - Form 8-K
STATERA BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
Statera Biopharma, Inc. announced that it has received $0.4 million in funding from Silverback Capital Corporation
Statera Biopharma, Inc. announced that it expects to receive $0.765 million in funding
STATERA BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Statera Biopharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
STATERA BIOPHARMA, INC. : Other Events (form 8-K)
STATERA BIOPHARMA, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
STATERA BIOPHARMA, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)
Statera Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
US Futures Lower Amid Earnings Reports, Ahead of Flash PMI Data
Top Premarket Gainers
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción STAB
  4. Acción STAB
  5. Noticias Statera Biopharma, Inc.
  6. Otros idiomas
-40% Oferta por Tiempo Limitado: Nuestras suscripciones le guían hacia las mejores inversiones del mañana.
APROVÉCHELO AHORA